SCHEMBL5547587

SCHEMBL5547587

O=[C]CCCN1CCN(C(=O)OCc2cccc(Cl)c2)CC1

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
ENPP2 Q13822 6/20 0.46
ATXN2 Q99700 1/20 0.45
CACNA1G O43497 3/20 0.44
HTR1A P08908 3/20 0.43
HRH1 P35367 2/20 0.43
DRD4 P21917 1/20 0.43
HTR2A P28223 1/20 0.43
OPRM1 P35372 1/20 0.43
HRH2 P25021 1/20 0.43
ATM Q13315 1/20 0.42
KCNH2 Q12809 1/20 0.42
HTR7 P34969 2/20 0.42
SIGMAR1 Q99720 1/20 0.42
HCAR2 Q8TDS4 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5542100 0.97 MEN1 (0.46) MEN1KMT2AENPP2ATXN2CACNA1G
SCHEMBL5544299 0.93 ENPP2 (0.47) MEN1KMT2AENPP2ATXN2HTR1A
SCHEMBL27610405 0.87 MEN1 (0.49) MEN1KMT2AENPP2ATXN2CACNA1G
SCHEMBL5537253 0.86 MEN1 (0.48) MEN1KMT2AENPP2ATXN2CACNA1G
SCHEMBL5540964 0.86 HRH1 (0.51) KMT2AENPP2CACNA1GHTR1AHRH1
SCHEMBL5546040 0.86 MEN1 (0.54) MEN1KMT2AENPP2HTR1AHRH1
SCHEMBL28015689 0.85 HRH2 (0.48) MEN1KMT2AENPP2ATXN2CACNA1G
SCHEMBL5537454 0.85 ENPP2 (0.49) MEN1KMT2AENPP2ATXN2HTR1A
SCHEMBL5547593 0.84 MEN1 (0.47) MEN1KMT2AENPP2ATXN2CACNA1G
SCHEMBL5542397 0.84 KMT2A (0.49) MEN1KMT2AENPP2ATXN2CACNA1G

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 MEN1 3295/4885KMT2A 4267/4885ENPP2 2915/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.